

# Claudia Cardone

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9337013/claudia-cardone-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38  
papers

1,045  
citations

18  
h-index

32  
g-index

73  
ext. papers

1,402  
ext. citations

4.3  
avg, IF

4.11  
L-index

#	Paper	IF	Citations
38	Colorectal Cancer: Locoregional Disease. <i>UNIPA Springer Series</i> , <b>2021</b> , 605-616	0.1	
37	Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. <i>European Journal of Cancer</i> , <b>2021</b> , 150, 203-210	7.5	1
36	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 15	12.8	6
35	Dual inhibition of TGF $\beta$ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. <i>Medical Oncology</i> , <b>2021</b> , 38, 24	3.7	2
34	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1529-1535	13.4	13
33	Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. <i>Annals of Oncology</i> , <b>2020</b> , 31, 30-40	10.3	58
32	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <i>Journal of Translational Medicine</i> , <b>2020</b> , 18, 405	8.5	64
31	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 1-10	7.5	9
30	The Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetings. <i>JAMA Oncology</i> , <b>2020</b> , 6, 926-927	13.4	2
29	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 86, 102023	14.4	19
28	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2019</b> , 38, 41	12.8	37
27	Genomic Profiling of Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. <i>Cancers</i> , <b>2019</b> , 11,	6.6	14
26	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 76, 22-32	14.4	131
25	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 845-855	6.1	30
24	Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. <i>Molecular Oncology</i> , <b>2019</b> , 13, 1827-1835	7.9	21
23	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. <i>Cancers</i> , <b>2019</b> , 11,	6.6	17
22	Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS731-TPS731	2.2	6

21	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , <b>2019</b> , 4, e000519	6	3
20	Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis. <i>Future Oncology</i> , <b>2018</b> , 14, 2905-2913	3.6	10
19	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , <b>2018</b> , 3, e000299	6	24
18	RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1121-1128	10.3	57
17	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 810-820	8.9	19
16	EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. <i>Gastroenterology</i> , <b>2017</b> , 153, 178-190.e10	13.3	51
15	Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. <i>Oncotarget</i> , <b>2017</b> , 8, 82773-82783	3.3	5
14	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , <b>2017</b> , 2, e000177	6	19
13	Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. <i>ESMO Open</i> , <b>2017</b> , 2, e000229	6	10
12	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 4675-4688	5.6	70
11	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 68305-68316	3.3	20
10	Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1055-1061	10.3	49
9	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 6345-61	5.6	69
8	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , <b>2016</b> , 1, e000107	6	8
7	Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. <i>ESMO Open</i> , <b>2016</b> , 1, e000086	6	8
6	Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. <i>Current Colorectal Cancer Reports</i> , <b>2015</b> , 11, 217-224	1	1
5	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4153-64	12.9	13
4	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS3634-TPS3634	2.2	2

3	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS789-TPS789	2.2	1
2	AXL is an oncotarget in human colorectal cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 23281-96	3.3	45
1	Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial		9